Abstract

Purpose of review There have been many debates, discussions, and published writings about the therapeutic value of cannabis plant and the hundreds of cannabinoids it contains. Many states and countries have attempted, are attempting, or have already passed bills to allow legal use of cannabinoids, especially cannabidiol (CBD), as medicines to treat a wide range of clinical conditions without having been approved by a regulatory body. Therefore, by using PubMed and Google Scholar databases, we have reviewed published papers during the past 30 years on cannabinoids as medicines and comment on whether there is sufficient clinical evidence from well-designed clinical studies and trials to support the use of CBD or any other cannabinoids as medicines.

Recent findings Current research shows that CBD and other cannabinoids currently are not ready for formal indications as medicines to treat a wide range of clinical conditions as promoted except for several exceptions including limited use of CBD for treating two rare forms of epilepsy in young children and CBD in combination with THC for treating multiple-sclerosis-associated spasticity.

Summary Research indicates that CBD and several other cannabinoids have potential to treat multiple clinical conditions, but more preclinical, and clinical studies and clinical trials, which follow regulatory guidelines, are needed to formally recommend CBD and other cannabinoids as medicines.

Keywords Cannabis · Cannabinoids · Delta-9-tetrahydrocannabinol · THC · Cannabidiol · CBD · Substance-related disorders

Introduction

Cannabis sativa, Linn., is a complex plant that has 567 chemicals of which 125 have been identified and characterized as cannabinoids, and the remaining chemicals are terpenes, flavonoids, and alkaloids. Most recently, Radwan et al. [1•] have identified several additional cannabinoid-like chemicals in C. sativa varieties grown in different regions of the USA. Several cannabinoids including cannabidiol (CBD), cannabichromene (CBC), cannabidiolic acid (CBDA), delta-9-tetrahydrocannabivarin (Δ9-THCV), cannabiol (CBN), delta-9-tetrahydrocannabivarinic acid (Δ9-THCAA), cannabigerolic acid (CBGA), cannabigerol (CBG), and delta-8-tetrahydrocannabinol (Δ8-THC) have been postulated to exhibit some medicinal value [2]. Based on the pharmacology of cannabinoids [3•], only two cannabinoids—Δ9-THC, the most psychoactive component of the plant, and CBD, a non-psychoactive component, have been extensively studied for their potential therapeutic applications. Both CBC and CBL (cannabicyclol) have no psychoactive properties [4]. While much work has been conducted with the most prominent cannabinoids, Δ9-THC and CBD, limited preclinical and almost non-existent clinical research exists on other cannabinoids. During the last decade, numerous investigators have published excellent systematic reviews of the published preclinical and clinical research suggesting that cannabinoids have potential to treat a wide range of clinical conditions [5, 6•, 7–11]. However, the research reviewed has been limited to only two cannabinoids, THC and CBD. Furthermore, many researchers have concluded that there is a lack of sufficient clinical research to support the use of any cannabinoid as medicine at this time and have recommended additional research.
In this narrative review, based on review of the published research, retrieved from PubMed and Google Scholar, and without duplicating what has already been published, we wish to report on the currently available clinical evidence on not only THC and CBD, but also on other discovered cannabinoids of C. sativa plant as medicinals and comment on whether the evidence is sufficient to support their use as medicines.

**Cannabinoids**

**Delta-9-tetrahydrocannabinol (Δ.₉-THC)**

Delta-9-tetrahydrocannabinol, the most psychoactive component of C. sativa plant, has been studied in numerous preclinical and clinical studies and clinical trials for its therapeutic value in treating a wide range of clinical conditions including nausea/vomiting [12], anorexia, appetite stimulation, sleep apnea [13], dystonia, Parkinson’s disease (PD), Alzheimer’s disease (AD), agitation associated with AD [14] to post-traumatic-stress-disorder (PTSD) and others with limited success.

In a small study of seven patients, treatment with THC (nabilone) was linked to improved motor scores on the Unified Huntington’s Disease Rating Scale (UHDRS) for chorea and dystonia. There was clinical improvement of gait, fine motor skills, and weight gain. There was less irritability, apathy, and less hypersalivation in some cases [15].

In a 14-week randomized, double-blind, crossover trial, Herrmann and colleagues [16] examined safety and efficacy of nabilone at doses of 1–2 mg in 39 patients (mean age of 87 years) with moderate-to-severe AD with agitation/aggression. They found that nabilone may be an effective treatment for agitation but suggested that sedation and cognition should be closely monitored. It is important to note that in the nabilone treatment group, there were a total of 51 adverse events including treatment-related sedation relative to 14 in the placebo group. In addition, one death occurred during the placebo washout phase (sudden death) following 6 weeks of the placebo phase, and one participant died on the last day of nabilone treatment (suspected stroke), after being titrated down to 0.5 mg.

Nabilone has been suggested as a treatment for PTSD [17], but according to Hindocha and colleagues [18], ‘most studies to date are small and of low quality, with significant limitations to the study designs precluding any clinical recommendations about its use in routine clinical practice.’ According to the investigators, the evidence is weak and additional well-designed, randomized, double-blind clinical trials are needed to support the use of cannabinoids in treating PTSD and associated symptoms like sleep disturbances and nightmares.

In a placebo-controlled, randomized trial, dronabinol at doses of 2.5 mg or 10.0 mg dose-dependently improved sleep apnea, self-reported sleepiness, and overall treatment satisfaction [13]. In the case of dystonia, in one randomized, double-blind, crossover placebo-controlled study of 15 patients, oral nabilone did not show any beneficial effects on generalized and segmental dystonia [19].

Both dronabinol and nabilone have been associated with adverse effects. Based on a survey of 10,010 subjects in a database in Germany, it was found that the use of dronabinol (65%), nabilone (0.3%) or Sativex (13%), for spasticity or anorexia/wasting was associated with adverse effects like tiredness, dizziness, dry mouth, and nausea. The potentially serious adverse effects of depression, suicidal ideation, delusions, hallucinations, dissociation, and misperceptions were each reported with frequencies higher than 0.1% [20].

Nabilone, as compared to placebo, failed to reduce cannabis use in 10 patients with cannabis use disorder [21]. Nevertheless, based on results from several preclinical and clinical studies and trials, synthetic THC (dronabinol, Marinol) [22–24] has been approved for the treatment of anorexia associated with weight loss in AIDS patients and chemotherapy-induced nausea and vomiting [25].

Nabilone [Cesamet®] is a synthetic cannabinoid like THC. Nabilone has been approved for the treatment of nausea and vomiting in patients undergoing cancer treatment [26]. THC in combination with CBD in a 1:1 ratio (nabiximols, Sativex®, an oral spray) is approved in 28 countries including Canada for treatment of moderate to severe spasticity due to multiple sclerosis (MS) in patients who have not responded adequately to other treatments. However, it has not yet been approved in the USA.

Whether THC alone will be further developed to treat other clinical conditions remains to be seen. However, due to its strong psychoactive properties and possible psychotogenic effects, it appears unlikely that THC alone will be further developed and approved as medicine for treating other clinical indication in near future. However, a non-psychoactive component of cannabis, CBD, has shown significant potential to treat several clinical indications, and these are further discussed in more detail below.

**Cannabidiol (CBD)**

CBD, one of the 125 cannabinoids present in Cannabis sativa, Linn., is a non-psychoactive chemical constituent [27] that acts via CB2 receptors in the body and other molecular targets discussed by Izzo and colleagues [28]. CBD is relatively safe. However, interactions between CBD and THC occur [29]. In a randomized, placebo-controlled trial, CBD alone, THC alone and CBD plus THC were tested for safety in a group of 36 (31 male) participants. Doses tested were placebo, CBD alone at 400 mg. THC alone at a dose
of 8 mg or THC plus 4 mg or 400 mg CBD. The low doses of CBD significantly (p < 0.0001) enhanced, while the high doses of CBD reduced the intoxication effects of THC. The enhancement of intoxication by low-dose CBD was particularly prominent in people with infrequent cannabis use and was consistent across objective and subjective measures. The investigators suggested that ‘these findings should be considered when recommending proportions of THC and CBD in cannabis plant matter whether used medicinally or recreationally by people without or people with less cannabis histories’ [30]. Furthermore, the use of CBD at oral dose of 200 mg daily for 10 weeks was also safe without any adverse psychological and cognitive effects in 20 individuals with frequent cannabis use [31].

CBD, given its non-addictive, anti-inflammatory, neuroprotective, and antioxidant properties, alone or in combination with other cannabinoids including THC, could potentially produce beneficial effects in PD, AD, MS, Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and cerebral ischemia [32]. However, additional clinical trials are needed to confirm its safety and efficacy in each of these neurological conditions. CBD in combination with THC or by itself has been tested in numerous small clinical studies and clinical trials showing that it may have potential to treat these and other conditions like anxiety, depression, and many other non-CNS conditions such as acne, heart disease, inflammation, liver disease and cancer. The available evidence is briefly reviewed below.

**Epilepsy:** The use of cannabis products in the treatment of epilepsy has long been of interest. CBD interacts with human 5-HT1A receptors of the hippocampus and temporal neocortex. At concentrations of 1 μM to 10 μM, the effect of CBD upon G(i/o) protein activation is limited. However, at a concentration of 100 μM, CBD acts as an inverse agonist of 5-HT1A receptors and thus could modify neuronal excitation and epileptic seizures in patients with drug-resistant mesial temporal lobe epilepsy (DR-MTLE; [33]). CBD, given its antiepileptic potential, could treat several forms of seizures [34–38].

Small clinical studies [39] and large randomized, double-blind, placebo-controlled clinical trials [40•, 41] have further confirmed antiepileptic effects of CBD. For an example, in a randomized, dose-ranging safety trial of CBD in Dravet syndrome, 34 patients (10, 8, and 9) were randomized to three CBD dose groups of 5, 10 and 20 mg/kg/day and 7 patients to the placebo group. Thirty-two (94%) patients completed the study. There were dose-related changes in plasma levels of CBD and its metabolites. The most common adverse effects were pyrexia, somnolence, decreased appetite, sedation, vomiting, ataxia, and abnormal behavior. Although the CBD-treated patients had more adverse effects than placebo, CBD was well tolerated [41]. CBD tested in a 12-week trial in patients with treatment-resistant epilepsy, was efficacious in reducing seizures [42]. CBD treatment was also linked to improved energy level, memory, control/helplessness, cognitive function, social interaction, and general global quality of life in children with epilepsy [43]. Results from these studies provide support for CBD in reducing the frequency of convulsions (tonic–clonic, tonic, clonic and atomic) seizures in patients with Dravet and Lennox-Gastaut syndromes [41].

CBD (Epidiolex) is approved for treating only two rare conditions of seizures—a rare form of epilepsy, known as Lennox-Gastaut and Dravet syndromes in patients two years of age and older [44], and a rare genetic condition known as tuberous sclerosis, where people suffer from seizures from benign tumors in the brain. Incidentally, it is important to note that as of February 8, 2022, of the 245 clinical trials registered on CBD [45], 31 trials are studying the efficacy of CBD for the treatment of one or more types of seizures [45].

** Autism:** Autism-spectrum disorder (ASD) is a neurodevelopmental disorder characterized by core deficits in social communication and restricted, repetitive patterns of behavior for which there are only two FDA-approved medications, risperidone, and aripiprazole, for ASD-associated irritability. Data from several small clinical studies suggest that cannabinoids and cannabinoids, including CBD and CBDV, although not approved by the FDA, may have potential in treating not only the core symptoms of ASD but also irritability and behavioral problems in ASD [46].

CBD-rich medical cannabis appears to be safe, efficacious, and tolerable for treating many ASD-associated symptoms [47]. For example, treatment with CBD (containing <3% THC) at an average daily dose of 0.7 mg/kg/d for 6.5 months was associated with improved behavioral problems, cognition, expressive language, and social interaction in 33 (27 males and 6 females; mean age of 7.7 ± 5.5 years) individuals with ASD [48]. In an observational study, CBD-enriched cannabis extract also was associated with improved ASD symptoms in 15 of the 18 ASD patients [49]. In a retrospective study of 60 children (mean age of 11.8 + 3.5, range 5.0 to 17.5 years) with ASD and severe behavioral problems, CBD-rich cannabis treatment was also safe and reduced the behavioral problems in 61% of patients, suggesting that it is feasible to conduct clinical trials to determine if CBD can be used to treat children with ASD [50]. Furthermore, Pretzsch and colleagues showed that CBD affects the brain function in patients with ASD. In an fMRI study of men with ASD, they showed that, compared to placebo, a dose of 600 mg CBD significantly increased the amplitude of low-frequency fluctuations in the cerebellar vermis and the right fusiform gyrus, the areas important for movement, language, and social processing [51].

**Schizophrenia:** Preclinical and clinical research show that CBD may have efficacy in treating schizophrenia and other psychotic disorders [52]. CBD may help improve positive symptoms of schizophrenia (hallucinations, delusions) and
negative symptoms of schizophrenia such as lack of emotion, loss of social functioning [53], possibly by increasing the naturally occurring endocannabinoid, anandamide [54]. According to Boggs et al., CBD could be as effective as prescription antipsychotics in treating psychosis, with the added benefit of generating fewer adverse effects. However, in a randomized, placebo-controlled trial, although CBD at an oral dose of 600 mg/d was well tolerated without worsening of mood, suicidality, or movement adverse effects, it was not efficacious in treating the cognitive impairment and other neuropsychiatric complications seen in patients with schizophrenia [55]. Taken together, the current evidence is unconvincing for supporting CBD use in psychotic disorders, and large well-designed clinical trials are required to assess the effects of CBD in psychotic and other psychiatric disorders [56•, 57].

Anxiety Disorders and Depression: Given CBD effects on serotonergic, GABAergic and other neurotransmitter systems, it may hold promise for treating disorders of generalized anxiety, social anxiety, panic, and post-traumatic stress [58]. Preclinical research shows that CBD may exert antidepressant effects by impacting serotonin pathways in the brain [59], and CBD may reduce anxiety through 5-HT1A receptor activation in rats [60]. Thus, CBD may act as an antidepressant [61], and via its effects on specific GABA_A receptor subtypes, as an anxiolytic agent [62]. When CBD was tested at an oral dose of 30 mg/kg orally in two ‘depressive-like’ genetic models of rats, Wistar Kyoto and Flinders Sensitive Line, the results showed that CBD also decreased immobility of rats in the forced swim test in males of both strains and in female of Wistar Kyoto strain, suggesting a role of CBD in treating mental disorders with prominent symptoms of helplessness and anhedonia (diminished feeling of joy or happiness) [63, 64].

Since CBD also increases the levels of naturally occurring endocannabinoids, such as anandamide, CBD may also hold promise for treating depression [59]. Since anxiety and depression occur in bipolar disorder, it has been suggested [65, 66] that CBD may stabilize mood in bipolar disorder too. However, CBD failed to improve acute manic episodes of bipolar in patients with mania [67], even though animal research suggested that CBD may mitigate potential mania-related brain damage [68].

Alzheimer’s and Parkinson’s diseases: CBD may prevent the development of amyloid plaques, a biological marker of AD, suggesting it could help treat AD [69, 70]. In vivo evidence where CBD coated by nano-chitosan showed good potential for reducing plaques, increasing brain CB1 and levels CB2, and improving learning and memory in Alzheimer’s rats [71] also suggests the possible utility of CBD in treating AD [72], but additional clinical research is needed to confirm its clinical potential in treating AD [32].

Limited data from controlled clinical trials also suggest efficacy of treating PD with CBD. In an exploratory double-blind trial [73], seven patients with PD were either treated with placebo, 75 mg/day of CBD or 300 mg/day of CBD. Neither motor functions nor general symptoms improved, although the quality of life of patients improved. CBD may potentially reduce PD-related symptoms like REM-sleep disturbances and improve the quality of life of PD patients [74].

In an open-label pilot study with six patients (4 men and 2 women) with a diagnosis of psychosis for at least 3 months, CBD at 150 mg/day for 4 weeks, in addition to their usual therapy, significantly decreased the total scores of Unified Parkinson’s Disease Rating Scale, with no adverse effects. These findings raise the possibility that CBD may be effective, safe, and well tolerated for the treatment of the psychosis in PD [75].

Movement disorders/Multiple Sclerosis: In an animal (C57/BL6 mice) model of multiple sclerosis, CBD promoted neuronal survival by inhibiting JNK and p38 MAP kinases, suggesting that the regulation of an important biological pathway, PI3K/Akt/mTOR, by CBD administration, could be a potential therapeutic target for MS [76]. With its anti-inflammatory and neuroprotective effects [77, 78], CBD was found to be efficacious in patients with MS with resistant spasticity [79]. CBD treatment also was associated with improved mobility in patients with MS [80], and in a small clinical trial, patients with moderate to severe MS and who were resistant to other drugs, improved in their spasticity-related symptoms when given Sativex (CBD-THC in 1:1 ratio; [81]).

Cannabinoids have been reported to be efficacious in treating dystonia symptoms in seven patients with Huntington’s disease [15]. Nevertheless, based on data from clinical trials, Sativex was found efficacious in treating MS-related neuropathic pain without adversely impairing driving performance [82] and has been approved in 28 countries including Canada. However, it has not yet been approved in the USA.

Trauma/Injuries/Stroke: Although there are no data from clinical studies to show that CBD would be effective in treating stroke and/or spinal cord injuries in humans, data from preclinical studies suggest that CBD could be tested for treating trauma, injuries, and/or stroke in humans. When CBD was applied to rats immediately before spinal cord injury, the rats displayed fewer problems with movement over the week following the injury, and there was less extensive damage in their spinal cords. These findings suggest that CBD possibly minimized the extent of the damage and allowed for a better overall recovery from the injury [83]. Similarly, in the case of stroke, CBD protected against brain damage in rats [84] and in mice [85].

Sleep Disorders: There is limited preclinical or clinical evidence for supporting the use of cannabinoids for treating sleep disorders. CBD promoted wakefulness in rats [86],
possibly via increasing levels of dopamine in brain regions responsible for wakefulness [87], suggesting that CBD could be further developed for treating narcolepsy. In a case report, CBD administration was linked to improved quality and quantity of sleep of a 10-year-old patient with PTSD, perhaps due to CBD’s anxiolytic effects [88].

**Inflammation/pain:** Preclinical research suggests that CBD, given its anti-inflammatory effects, could potentially treat gastrointestinal GI diseases such as colitis [89], inflammatory bowel disease (IBD) [90], and Crohn’s disease [91]. In a randomized, placebo-controlled trial with 20 patients with Crohn’s disease, CBD at 10 mg/d, po, was well tolerated but not efficacious in treating Crohn’s disease, possibly due to small dose of CBD, the smaller number of patients, or lack of synergism with other cannabinoids, or other possibilities [91].

CBD has also shown analgesic effects against incision-related pain in rats by reducing the sensory perception and emotional effects of pain [92]. CBD could be effective in treating chronic pain, arthritic pain, or cancer-related pain. Research suggests that CBD may be most effective in treating chronic and neuropathic pain, while it has limited use in treating short-term pain. Although Darkovska-Serafimovska et al. [93] suggest that CBD could treat cancer pain with mild to moderate adverse effects such as drowsiness, nausea, vomiting, and dry mouth, Mucke and colleagues [94] concluded that ‘the potential benefits of cannabis-based medicine (herbal cannabis, plant-derived or synthetic THC, THC/CBD oromucosal spray) in chronic neuropathic pain may be outweighed by their potential harms.’ Hauser et al. [95] conducted a systematic review of the publications between 2009 and 2017 and concluded that ‘there is limited evidence for a benefit of THC/CBD spray in the treatment of neuro-pathic pain, and there is inadequate evidence for any benefit of cannabinoids (dronabinol, nabilone, medical cannabis, or THC/CBD spay) to treat cancer pain, pain of rheumatic or GI origin, or anorexia in cancer or AIDS.’

Treatment with cannabis-based medicines has been associated with central nervous and psychiatric adverse effects. However, the public perception of the efficacy, tolerability, and safety of cannabis-based medicines in pain management and palliative medicine conflicts with the findings of systematic reviews and prospective observational studies conducted according to the standards of evidence-based medicine. On the other hand, when Whiting and colleagues [45] conducted a systematic review of 79 clinical trials where dronabinol, nabilone, CBD, nabiximols, or cannabis was tested for the treatment of chronic pain or spasticity, they found moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. According to them, there is low-quality evidence for supporting the use of cannabinoids for treating or improving chemotherapy-associated nausea and vomiting, weight gain in HIV infection, sleep disorders, and Tourette syndrome. In addition, cannabinoids have been associated with short-term adverse effects including dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucinations.

**Nausea/Appetite Stimulation:** The proposed use of CBD for nausea is relatively more recent. Preclinical research [96] suggests that CBD may stop nausea and vomiting in humans. CBD may be particularly helpful in treating nausea in patients who are not getting relief from prescribed anti-nausea drugs [97]. However, more clinical research is needed to support its use for treating nausea/vomiting in humans.

In terms of appetite-stimulating effects, there are no studies in humans where CBD stimulated appetite. On the other hand, smoked cannabis did increase appetite and weight gain in patients with HIV/AIDS [98] without affecting viral load, and the oral THC also resulted in weight gain in patients with cachexia (extreme loss of weight) [25]. More research is needed to study the effects of CBD and other cannabinoids on appetite.

**Substance Use Disorders:** Limited research suggests that CBD may have potential in treating substance use disorders including those involving tobacco, cannabis, and opiates. In a 2013 study [99], a group of 24 individuals with tobacco smoking were randomized to receive an inhaler of CBD or placebo for one week. They were instructed to use the inhaler whenever they felt a craving to smoke. Over the course of one week, those taking the CBD inhaler reduced their number of cigarettes smoked by 40% while those receiving the placebo inhaler did not decrease the number of cigarettes they smoked.

In a randomized, double-blind, placebo-controlled crossover study of people with tobacco use disorder, a single dose of 800 mg oral dose of CBD reduced the salience and pleasantness of cigarette cues, compared with placebo, after overnight cigarette abstinence. However, CBD did not influence tobacco craving or withdrawal or any subjectively rated adverse effects [100].

In the case of cannabis use disorder (CUD), Beale and colleagues [101] treated individuals with regular cannabis use with 200 mg/day of CBD over a 10-week period. CBD treatment appeared to reduce neuroanatomical damage in the hippocampus without generating any significant adverse effects, thereby suggesting a neuroprotective role of CBD against possible brain structural harm conferred by chronic cannabis use. Beale et al. [101] further suggested that CBD might be a useful adjunct in the treatment of CUD and a range of clinical disorders characterized by hippocampal pathology (e.g., schizophrenia, Alzheimer’s disease, and major depressive disorder). Adaptive Bayesian trials provide a platform for sequential learning. They assume the ‘a priori’ knowledge of probability models, in such a way that
it is possible to build more precise models of phenomena starting from experimental data and then use the models to make predictions. In a phase 2a, double-blind, placebo-controlled, randomized, adaptive Bayesian trial, Freeman and colleagues [102•] showed that synthetic CBD at doses of 400 mg (2 capsules of 100 mg each twice daily) or 800 mg (2 capsules of 200 mg each twice daily) for 4 weeks, compared to placebo, was safe and efficacious in reducing cannabis use in patients with CUD. The dose of 200 mg was not efficacious.

In another randomized, double blind, placebo-controlled trial, nabiximols combined with motivational enhancement therapy and cognitive behavioral therapy (MET/CBT) was well tolerated and reduced cannabis use and craving but not withdrawal symptoms in people with chronic cannabis use [103•]. Future trials with higher doses of CBD were recommended for patients with severe CUD.

In a study of 128 cannabis dependent patients with CUD (98 men and 30 women), treatment with placebo or nabiximols (47.5 mg THC + 44 mg CBD; Sativex), combined with psychosocial interventions appeared efficacious. Thus, they may represent a safe approach for reducing cannabis use among treatment-seeking individuals with CUD [104].

In a subsequent study, Lintzeris and colleagues [105] also reported that the benefits of treatment incorporating nabiximols with psychosocial interventions in reducing cannabis use appears to persist for up to 3 months after the cessation of treatment, leading the authors to propose a stepped care model of treatment. In yet another double-blind randomized clinical inpatient trial with a 28-day follow-up study [106], a group of 51 treatment-seeking individuals with DSM-IV-TR cannabis dependence received a 6-day regimen of nabiximols (maximum daily dose, 86.4 mg of Δ9-THC and 80 mg of CBD) or placebo with standardized psychosocial interventions during a 9-day admission. Nabiximols attenuated cannabis withdrawal symptoms and improved patient retention in treatment. However, placebo was as effective as nabiximols in promoting long-term reductions in cannabis use following medication cessation. Nevertheless, the data support further evaluation of nabiximols for management of CUD and withdrawal in treatment-seeking populations.

Other studies also suggest a positive profile of CBD in treating CUD. Solowij and colleagues [31] reported that CBD was well tolerated by people with chronic cannabis use without affecting their cognitive or psychological function. The participants reported reduced euphoria when smoking cannabis, experienced significantly fewer depressive and psychotic-like symptoms at post-treatment relative to baseline, and exhibited improvements in attentional switching, verbal learning, and memory. Increased plasma CBD concentrations were associated with improvements in attentional control and beneficial changes in psychological symptoms. Greater benefits were observed in people with more severe relative to less severe cannabis use. The investigators concluded that prolonged treatment with CBD appeared to have promising therapeutic effects for improving psychological symptoms and cognition in people with regular cannabis use and that CBD might be a useful adjunct treatment for CUD.

In a case report, CBD also helped symptoms of cannabis withdrawal in a 19-year-old woman with CUD [107]. Shannon and Opilla-Lehman [108] reported a case where CBD oil decreased the addictive use of marijuana and provided anxiolytic and sleep benefits. ‘The patient was a 27-year-old male who presented with a long-standing diagnosis of bipolar disorder and a daily use of marijuana. In the described intervention, the only change made to the patient’s treatment was the addition of CBD oil with the dosage gradually decreasing from 24 to 18 mg. With use of the CBD oil, the patient reported being less anxious, as well as settling into a regular pattern of sleep. He also indicated that he had not used any marijuana since starting the CBD oil. With the decrease in the dosage to 18 mg, the patient was able to maintain his abstinence of marijuana’ [108]. Whether they would respond to treatment with another cannabinoid remains unknown. Furthermore, research also shows that dronabinol, nabilone, or nabiximols, either alone or in combination with other drugs, may have promise in reducing cannabis withdrawal symptoms, possibly in a dose-dependent manner [109]. Finally, in the case of opioid use disorder (OUD), Hurd and colleagues [110•] reported that CBD reduced cue-induced craving and anxiety in people with OUD but suggested that larger clinical trials are needed to confirm the efficacy of CBD in treating the condition. The National Academy of Sciences [111] also suggests that CBD has a potential to treat a wide range of health ailments but more clinical research is needed before it is used for treating conditions for which it is not yet approved.

Miscellaneous Effects: CBD has been tested for treating diabetes [112], hemodynamic conditions [113, 114], ischemic stroke [115], apoptotic cell proliferation and anticancer effects [116], and viral hepatitis [117]. In addition, based on the anti-inflammatory, cardioprotective, and anti-angiogenesis effects of CBD [118], protection of endothelial function [119] shown in preclinical research, and by blocking ‘cytokine storm’ effects, it may warrant further evaluation in treating patients with multiple complications of coronavirus disease-19 (COVID-19). However, the investigators cautioned that only highly pure forms of CBD showed significant effects on COVID-19 complications [120]. More clinical research is needed to investigate CBD’s potential for treating these indications. Although cannabis and its cannabinoids have been proposed as therapies for cancer [5, 121–126], more studies are needed before any cannabinoid(s) can be recommended for treating cancer.
Cannabichromene (CBC)

Cannabichromene is a major, non-psychotropic, anti-inflammatory and biologically active phytoannabinoid component of *C. sativa* plant [127, 128]. CBC selectively reduces inflammation-induced gastric hypermotility in mice [4]. CBC acts as an analgesic by interacting with several target proteins involved in nociceptive control, suggesting that CBC may be a useful therapeutic agent for treating pain. CBC seems to work via CB1 and TRPA1 (transient receptor potential-ankyrin type 1) receptors [129]. CBC may also exert antidepressant-like actions and thus may contribute to the overall mood-elevating properties of cannabis [130]. In addition, CBD may induce apoptosis and inhibit the growth of several cancer cell lines including breast cancer cells, suggesting that CBC could be further developed for treating cancer [131]. CBC has positive effects on mouse neural stem/progenitor cells (essential for brain function) and could possibly be investigated to treat neuroinflammatory conditions including seizures/epilepsy [132]. Based on its action on inflammatory cytokines like MCP-2 [monocyte chemotactic protein], interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor (TNF-alpha), it could be developed for treating allergic contact dermatitis [133]. Given its anti-inflammatory activity on human skin sebocytes, CBC may have potential for treating acne [134]. Long-term safety, preclinical, and clinical studies and clinical trials are needed to investigate CBC’s potential as a medicine.

Cannabidivarin (CBDV)

CBDV, synthesized from cannabigerolic acid (CBGA) in the presence of CBD synthase, is non-psychoactive and seems to have similar applications in medicine as CBD to treat seizures and epilepsy [34, 135–139]. CBDV may act via CB1 and CB2 receptors and modulate neuronal excitability and neuroinflammation via several mechanisms including the expression of epilepsy-related genes (Fos, Casp3, Ccl3, Cc14, Npy, Arc, Penk, Cam2a, Bdnf, and Egr1) in the hippocampus, neocortex, and prefrontal cortex [140]. Based on data from animal models of seizures [139], CBDV could be developed for treating different forms of epilepsy. Several clinical studies/trials are underway to determine if CBDV could be used to treat epilepsy [135]. Given its anti-inflammatory activity on human sebocytes, it may have potential for treating acne [134]. Since it also acts as a CB1 receptor inverse agonist, it may have potential for treating nausea [141].

Given effects of CBD on brain excitatory-inhibitory systems in ASD [51, 142], CBDV may similarly have potential for treating ASD [50, 143–145]. In a double-blind, randomized-order, crossover design study using magnetic resonance spectroscopy (MRS), Pretzsch and colleagues [142] compared glutamate (Glx = glutamate + glutamine) and GABA + (GABA + macromolecules) levels following placebo (baseline) and 600 mg CBDV in 17 healthy men with ASD and 17 healthy men without ASD. They found that CBDV significantly modulated the glutamate-GABA system in the basal ganglia but not in frontal regions.

Finally, the investigators [146] prospectively collected data from 188 ASD patients treated with cannabis oil containing 30% CBDV and 1.5% THC for 6 months and found that 30%, 53.7%, 6.4% reported a significant, moderate, and slight improvement, respectively. While eight (8.6%) patients had no change in their condition, 23 patients (25.2%) experienced at least one adverse effect; the most common was restlessness (6.6%). CBDV was well tolerated by ASD patients suggesting that CBDV appears to be a safe and effective option to relieve symptoms associated with ASD [146].

Tetrahydrocannabivarin (THCV)

Tetrahydrocannabivarin is a non-psychoactive component of the cannabis plant. Based on its numerous pharmacologic effects including anti-psychotic, anti-inflammatory, immunomodulatory properties, effects on 5-HT1A, CB1 and CB2 receptors, and on metabolism, it has been suggested that THCV has the potential to treat a wide range of clinical conditions including schizophrenia, epilepsy, nausea, obesity, and some skin conditions [134]. THCV also has potential to treat oxidative stress and inflammation induced conditions like cancer, pain, neurodegeneration, cardiovascular disease, obesity and metabolic syndrome, diabetes and diabetic complications, diabetic cardiovascular dysfunction, nephropathy, retinopathy, and neuropathy [147].

Regarding anti-inflammation, Batkai and colleagues [148] showed that Δ(8) -THCV activated CB2 receptors in vitro and decreased tissue injury and inflammation in vivo. The model involved ischemia-perfusion hepatic injury, and the effect was observed partly via CB2 receptor activation.

In a placebo-controlled, double-blind, crossover pilot trial of 10 cannabis-using men (<25 occasional uses), THCV at an oral dose of 10 mg protected against THC-induced delayed verbal recall and increased heart rate. However, THCV potentiated the THC effects of memory intrusions [149]. Together, more extensive well-designed clinical studies and trials are needed to investigate THCV’s potential [150].

Cannabigerol (CBG)

Cannabigerol, a minor component of the cannabis plant, is the parent molecule from which other cannabinoids are synthesized. CBG has shown positive effects on neuroinflammatory and neurodegenerative processes through cell membrane cannabinoid receptor-dependent and -independent mechanisms, and modulation of the expression of genes
involved in MS pathophysiology. Thus, CBG could be investigated as a potential treatment for MS and possibly other neuroinflammatory diseases [151]. Given CBG’s antioxidant and anti-inflammatory effects seen in in vivo studies, it could also be investigated as a potential treatment for inflammatory conditions like colitis [89], IBD [123], ‘acne-like condition,’ dry skin syndrome [134], and psoriasis [152]. Given its inhibitory effects on growth of colorectal cells, it could also be developed for the prevention and treatment of colorectal and other cancers including breast cancer [123, 153].

**Cannabivarın (CBV)**

Cannabivarın (CBV) was discovered in 1971 as one of the cannabinoids in hashish [154]. However, to date, no data are available from any preclinical or clinical studies.

**Safety of cannabinoids, drug-drug interactions among cannabinoids and other medications, and role of genetics of cannabis variants**

Cannabinoids are associated with short-term adverse events including dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, hallucinations, sedation [45], and possibly death [16]. In addition, cannabinoids may also interact with other drugs used in clinical practice via several drug-metabolizing cytochrome-p-450 (CYP450) isoforms including CYP1A2, CYP2B6, CYP2C9, and CYP2D6 by THC; CYP3A4, CYP2B6, CYP2C9, CYP2D6, and CYP2E1 by CBD; and CYP2B6, CYP2C9, and CYP2E1 by cannabinol [155].

For example, the CYP2C9-mediated metabolism was inhibited by several cannabinoids with estimated $K_i$ values of 0.2–3.2 μM. Of the cannabinoids like CBD, CBG, CBDV, CBN, THC, THCA, and THCV tested, most inhibited CYP2C19, whereas CYP2D6, CYP3A4, and CYP2B6 were either not affected or only partially inhibited by the cannabinoids [156]. THC and CBD may inhibit several CYP450 enzymes in vitro, whereas smoke from cannabis may induce one specific CYP450 enzyme. In the case of dronabinol, it is primarily metabolized by CYP2C9, which is responsible for the formation of the major active metabolite (11-hydroxy-delta-9-THC). Individuals with less CYP2C9 activity (‘CYP2C9 poor metabolizers’) have two–threefold increased exposure to dronabinol from similar doses and thus appear at an increased risk of adverse effects including sedation, physical weakness, facial flushing, and palpitations. Further, the FDA-approved drug label for dronabinol recommends monitoring for the increased adverse reactions that could potentially occur in individuals with genetic variants associated with diminished CYP2C9 function [157]. Along with a lack of robust clinical studies, inconsistencies in chemical compositions and methods of ingestion of various cannabis products make it challenging to clinically assess for and predict interactions between cannabis and other medications.

In addition to potential pharmacokinetic interactions relating to differences in drug metabolism, potential pharmacodynamic interactions (e.g., adverse effects secondary to the use of cannabis with other psychoactive drugs) are also important to consider [158]. Further, the high frequency and increasing use of cannabis also invites the need for clinicians to familiarize themselves with potential drug-drug interactions in people receiving select psychotropic agents, and additionally consuming medical and/or recreational marijuana [8, 159].

Despite being a controversial crop, *Cannabis sativa* L. has a long history of cultivation throughout the world. As mentioned, following recent legalization in Canada, *Cannabis* is emerging as an important plant for both medicinal and recreational purposes. It is important to recognize that recent progress in genome sequencing of both cannabis and hemp varieties allow for systematic analysis of genes coding for enzymes involved in the cannabinoid biosynthesis pathway [160]. Single-nucleotide polymorphisms in the coding regions of cannabinoid synthases play an important role in determining plant chemotype [161].

In addition, recent genomic research shows that the NIDA-supplied cannabis varieties, used in basic and clinical research, are divergent from the private legal commercial varieties in terms of cannabinoids profile. The NIDA-supplied cannabis varieties lack diversity in the single-copy portion of the genome, the maternally inherited genomes, the cannabinoid genes, and in the repetitive content of the genome. Therefore, investigators [162] have suggested that results based on NIDA’s varieties may not generalize regarding the effects of cannabis after consumption.

A better understanding of how cannabis variants may influence enzyme activity and accumulation of cannabinoids will allow for breeding of novel cultivars with desirable cannabinoid profiles. For future study and development of pure compounds, comprehension of system biological approaches is required to accomplish further development of cannabis as an FDA-approved medication for distinct diseases. In addition, since synthetic CBD is now available and both natural, plant-extracted CBD are pharmacologically similar [163], it remains to be seen whether synthetic CBD will become the standard chemical in research and/or clinical practice.

Finally, it is important to note that in its 92-year history, the US FDA has approved only two botanical drugs as medicines (whole plant-products—such as sinocatechins, Veregen® for treating genital and perianal warts and erofelemer, Mytesi™ for AIDS-associated diarrhea), mainly because of immense technical/chemical and other problems in obtaining well-characterized products from chemically
complex plant. Therefore, it seems highly unlikely that the FDA will approve cannabis plant per se as a medicine, since its purified individual chemical components like THC, CBD or other cannabinoids may be readily obtained and used in research as well as in treatment.

Discussion

In general, of the hundreds of chemical constituents found in a plant, there is one main pharmacologically active chemical constituent like nicotine (Tobacco plant), cocaine (Erythroxylon coca), morphine (Papaver somniferum), and so on. But research shows that Cannabis sativa, Linn., has been an important plant used in folk medicine [164] for centuries for its uniqueness in the plant kingdom such that it contains not one but several pharmacologically active chemical constituents with therapeutic potential. As discussed above, of the 125 cannabinoids, although only two (THC and CBD) have been more extensively studied for their pharmacological effects and therapeutic effects, other cannabinoids discussed above also show pharmacological activity and possible therapeutic value. There are several cannabinoids-related or cannabis-like pharmacologically active products that seem to act via either CB1 and/or CB2 receptors, but only four products have been approved as therapeutics. Other products have been either withdrawn by the manufacturer for failed efficacy or due to observed serious adverse reactions (Table 1) [Table 1 goes here].

Synthetic THC in the form of Marinol and Nabilone have approved as medicines for the treatment of chemotherapy-associated nausea and vomiting, and as an appetite stimulant in patients with AIDS. Further, in combination with CBD (as Sativex) THC is also approved as medicine for the treatment of MS-associated spasticity in several countries, although not in the USA. However, due to its addictive properties and adverse effect profile, THC may not be an ideal candidate for further development as a medicine. Of the many cannabinoids, arguably the most studied is CBD. Several clinical studies and trials resulted in its approval as medicine for treating two rare forms of epilepsy: Lennox-Gastaut and Dravet syndromes in young children and seizures from rare tumors in the brain. However, CBD is not approved as a medicine for treating any other clinical indication even though, in an estimated annual 20 billion market, it is often being promoted, sometimes like a ‘wonder drug’ for treating multiple clinical indications. On the other hand, research clearly suggests that it has potential for further development. Nevertheless, there is a need for conducting clinical studies and clinical trials specific for each separate clinical indication as evident from several clinical trials currently underway (https://clinicaltrials.gov).

Similarly, in the case of the other cannabinoids reviewed above, each needs further testing. For example, given its neuroinflammatory effects, cannabichromene (CBC) could be investigated for treating seizures; given its effects on inflammatory cytokines, it could be developed to treat allergic dermatitis, and given its antifibrotic effects, could be developed for treating acne. For its neuroinflammatory effects, cannabidivarin (CBDV) also could be investigated for treating seizures, and for its anti-inflammatory effects on human sebocytes, developed for treating acne. Like CBD, tetrahydrocannabivarin (THCV) has antipsychotic, anti-inflammatory, and immunomodulation effects and thus could be investigated for treating a wide range of clinical conditions including schizophrenia, epilepsy, obesity, nausea, neuropathy, retinopathy nephropathy, pain, and dermal conditions like dermatitis and acne [147]. Given its antioxidant, anti-inflammatory, and modulation of genetic expression effects, cannabigerol (CBG) could be investigated for treating dermal conditions like dermatitis, acne, colorectal cancer, and colitis. Thus, the cannabinoids discussed above have potential to treat a wide range of clinical conditions, for which several clinical trials are in various stages of progress as registered at: https://clinicaltrials.gov and that we briefly summarize in Table 2.

(Table 2 goes here).

Finally, we should be cognizant of significant variability in the CBD content and unknown level of adulteration with newly discovered cannabinoids, many of which are CBD-like or THC-like [165]. These may impact on safety and efficacy of CBD and other cannabinoids sold as medicines. It is also important to utilize an evidence-based approach, including when considering substances considered illegal under US federal law. Clinicians, especially addiction physicians, should weigh risks and benefits of the use of cannabinoids or medical marijuana in their patients and should ensure that patients asking for prescription for unapproved cannabinoids have tried other treatment modalities with higher levels of evidence for use when available and appropriate [166]. We believe that researchers and clinicians may want to engage in the systematic investigation of cannabinoids including CBD as a therapeutic, instead of promoting, recommending, or marketing any of these cannabinoids without these having gone through FDA-recommended systematic drug development guidelines. These include conducting studies of pharmacological effects, mechanisms of drug action, pharmacokinetic/pharmacodynamic and drug-drug interactions, and long-term safety studies, and in compliance with the good manufacturing practice (GMP), good laboratory practice (GLP), and good clinical practice (GCP) guidelines for conducting Phase I, Phase II, and pivotal Phase III clinical trials for each specific clinical indication. In view of the substantial cost of conducting clinical research and FDA-required clinical trials, it remains to be seen whether pharmaceutical companies will venture to develop CBD or any other cannabinoid as therapeutics for treating a wide range of clinical indications.
Table 1  FDA-approved and non-approved Cannabis-based Pharmaceuticals (Pharmaceutical Drugs Based on Cannabis—Medical Marijuana—ProCon.org; accessed 07,232,022) (FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) | FDA; accessed 07,232,022)

| Product          | Manufacturer                  | Cannabis-related properties                  | Potential/approved indication                                                                 | Current approval status |
|------------------|-------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------------|------------------------|
| Dronabinol/Marinol | Solvay pharmaceuticals       | Synthetic THC                               | Chemotherapy-related nausea/vomiting; appetite stimulation in AIDS patients                     | Approved               |
| Nabilone/Cesamet  | Valeant Pharmaceuticals       | Synthetic cannabinoid like THC              | Chemotherapy-related nausea/vomiting                                                             | Approved               |
| CBD/Epidiolex     | GW pharmaceuticals           | CBD                                         | Epilepsy/LG-Dravet syndrome                                                                    | Approved               |
| Nabiximols/Sativex| GW pharmaceuticals           | CBD + THC in 1:1 ratio, oral mouth spray     | MS-associated Neuropathic pain and spasticity                                                    | Approved in 28 countries but not in the US |
| Dexanabinol       | Solvay pharmaceuticals       | Synthetic non-psychotic cannabinoid that blocks NMDA receptors and COX-2 cytokines and chemokines | Neuroprotective for use after cardiac surgery, regain memory and brain function following traumatic brain injury, possible anti-cancer | NOT approved due to failed efficacy |
| CT-3 (ajulemic acid) | Indevus pharmaceuticals     | Synthetic, potent analog of THC metabolite, THC-11-oic acid | MS-associated spasticity; anti-inflammatory for arthritic pain                                  | NOT approved           |
| Cannabinor (PRS-211,275) | Pharmos                   | Synthetic cannabinoid that binds to CB2 receptors | Anti-inflammatory for chronic neuropathic pain, bladder control                                 | NOT approved           |
| HU-308            | Pharmos                       | Synthetic cannabinoid that binds to CB2 receptors | Anti-inflammatory; hypertension                                                                | NOT approved           |
| HU-331            | Cayman chemicals             | Synthetic cannabinoid that binds to CB1 and CB2 receptors | Memory, weight loss, appetite stimulant, neurogeneration, tumor surveillance, analgesia, inflammation | NOT approved           |
| Rimonabant/Acomplia | Sanofi/Aventis               | Synthetic chemical blocks endocannabinoids | Anti-obesity (appetite suppression)                                                              | NOT approved; Sanofi withdrew due to adverse effects of suicidal ideations |
| Taranabant/MK-0364 | Merck                        | Synthetic chemical targets appetite controlling receptors; acts via CB1R receptors | Anti-obesity                                                                                        | NOT approved; Merck stopped further development due to ADRs like anxiety and depression |

ADRs = adverse drug reactions
Table 2 Therapeutic Potential of Cannabinoids Based on Research Reviewed

| Cannabinoid       | Pharmacologic activity                                                                 | Potential Indication                                                                 |
|-------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Cannabidiol       | Anti-inflammatory, neuroprotective, antioxidant, cardio-protective, anti-angiogenesis   | Anxiety (94*), Alzheimer’s, autism, depression (61*), epilepsy/seizures (44*), inflammation, multiple sclerosis (7*), pain (64*), Parkinson’s disease (4*), trauma, colitis, skin disorders, substance use disorders (15*) |
| Cannabichromene   | Anti-inflammatory, neuroprotective                                                       | Epilepsy, skin disorders                                                             |
| Cannabivarin      | Anti-inflammatory, neuroprotective                                                       | Autism, epilepsy, skin disorders                                                     |
| Tetrahydrocannabin | Anti-inflammatory, neuromodulatory, antioxidant, cardio-protective                       | Cancer, cardiovascular dysfunction, diabetes, neuropathy, nephropathy, pain, retinopathy |
| Cannabigerol      | Anti-inflammatory, neuroprotective, anti-proliferative                                   | Inflammation, pain, multiple sclerosis, colitis, skin disorders, cancer               |

The clinical conditions summarized above are where individual cannabinoids have shown some clinical evidence supporting further development as a therapeutic; *= number of clinical trials investigating clinical conditions registered at: https://clinicaltrials.gov

Conclusion

Based on preliminary preclinical and clinical research, cannabinoids could be further investigated for their potential in treating a wide range of clinical conditions. For their effects on neuroinflammation, inflammatory cytokines, psychosis, fibrosis, and immunomodulation, many of these cannabinoids may be further investigated for treating clinical indications ranging from seizures/epilepsy in adults, schizophrenia, obesity, nausea, neuropathy, retinopathy nephropathy, pain, and dermal conditions like dermatitis and acne [147]. Finally, it is less likely that THC, given its strong psychoactive properties and other potential adverse effects, would be further developed as a medicine. However, CBD has potential to treat a wide range of clinical conditions/diseases. Currently, CBD seems most indicated for treating two rare forms of epilepsy in young children and in combination with THC as Sativex as these indications have been approved in several other countries except in the USA. Many investigators and medical organizations like the National Academy of Sciences [111] and the American Psychiatric Association [167] recommend that additional basic and clinical research is needed before CBD, or any other cannabinoids are approved by a regulatory agency like the US Food and Drug Administration for clinical use. None of the other cannabinoids discussed above should be currently considered formally as medicines to treat unapproved clinical indications at this time as further investigations are needed.

Acknowledgements Dr. Jag H. Khalsa is grateful to the US National Institute on Drug Abuse, a component of the National Institutes of Health, Department of Health and Human Services, for an opportunity to serve as a Special Volunteer following his retirement on October 31, 2017, after 30+ years as the Chief, Medical Consequences of Drug Abuse and Infections Branch.

Author Contributions: JHK contributed to the conceptualization and original draft preparation; GB, SBM, MG, KB, and MP contributed to the inputs at various levels of review and writing; all authors have read and agreed to the published version of the manuscript.

Funding: SBM received funding from NIH grants: R01NS066801 and R01AG 054325; other co-authors did not receive any external funding.

Declarations

Institutional Review Board Statement Not applicable.

Informed Consent Statement Not applicable.

Disclaimer The statements in this paper are of the authors’ only and do not reflect the official position of any of their organizations.

Conflicts of Interest The authors declare no conflict of interest.

References

Papers of particular interest, published recently, have been highlighted as:
- Of importance

1. Radwan MM, Chandra S, Gul S, ElSohly MA. Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis. Molecules. 2021;26:1–29. In a most recent publication, the investigators report that cannabis is a complex plant and contains a mixture of chemical constituents characterized as cannabinoids like THC, CBD and several others but also new THC-like and CBD-like cannabinoids. The plant also contains non-cannabinoid-type constituents that include non-cannabinoid phenols, flavonoids, terpenes, alkaloids, and others.

2. Smith DE. Review of the American Medical Association Council on Scientific Affairs report on medical marijuana. J Psychoactive Drugs. 1998;30:127–36.

3. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515–27. Here the investigators have provided an excellent overview of the recent pharmacological advances, novel mechanisms of action, and potential therapeutic applications of such non-psychotropic plant-derived cannabinoids, with special emphasis on cannabidiol, the
possible applications of which have emerged in a wide range of clinical conditions including inflammation, dia-

5.

7.

9.

11.

13.

15.

17.

19.

21.

23.

25.

27.

29.

31.

33.

35.

41.

43.

45.

47.

49.

51.

53.

55.

57.

59.

61.

63.

65.

67.

69.

71.

73.

75.

77.

79.

81.

83.

85.

87.

89.

91.

93.

95.

97.

99.

101.

103.

105.

107.

109.

111.

113.

115.

117.

119.

121.

123.

125.

127.

129.

131.

133.

135.

137.

139.

141.

143.

145.

147.

149.

151.

153.

155.

157.

159.

161.

163.

165.
Epileptogenesis and Related Comorbidities. Mol Neurobiol. 2018;55:6956–64.

36. Reddy DS. The Utility of Cannabidiol in the Treatment of Refractory Epilepsy. Clin Pharmacol Ther. 2017;101:182–4.

37. Perucca E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? J Epilepsy Res. 2017;7:61–76.

38. Lippiello P, Balestrini S, Leo A, Coppola A, Citraro R, Elia M, Russo E, De Sarro G. From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We? Curr Pharm Des. 2016;22:6426–33.

39. Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome. Pediatr Neurol. 2017;71:18-23.e12.

40. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–96. In a 24-center trial, CBD was found to be efficacious for the treatment of patients with drop seizures associated with Lennox-Gastaut (LGE) syndrome. It is important to note that although CBD was well tolerated, there were adverse events in 74 (86%) of 86 patients in the CBD group and 59 (69%) of 85 patients in the placebo group; most were mild or moderate. The most common adverse events were diarrhea, somnolence, pyrexia, decreased appetite, and vomiting. 12 (14%) patients in the CBD group and one (1%) patient in the placebo group withdrew from the study because of adverse events. One patient (1%) died in the CBD group, but this was considered unrelated to CBD.

41. Devinsky O, Patel, A.D., Thiele, E.A., Wong, M.H., Appleton, R., Harden, C.L., Greenwood, S., Morrison, G., Sommerville, K., Group, G.P.A.S. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204–11.

42. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloix F, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label intervention trial. Lancet Neurol. 2016;15:270–8.

43. Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017;58:e96–100.

44. U.S. Food & Drug Administration approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018:2022.

45. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, de Lima JD. Medical use of cannabis. Cannabidiol: a new light for understanding pain and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology. 2018;235:1923–32.

46. Khoury JM, Neves M, Roque MAV, Queiroz DAB, Corrêa de Freitas AA, de Fátima A, Moreira FA, Garcia FD. Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry. 2019;20:101–16. In this interesting review, the investigators, based on a review of several hundred published reports, concluded that in most studies, results did not reach significance; that there was no evidence regarding major depressive and bipolar disorders; the level of evidence for cannabis withdrawal was B; for cannabis addiction is C2, treatment of positive symptoms in schizophrenia and anxiety in social anxiety disorder it was C1. The most frequently reported AEs were sedation and dizziness. The evidence regarding efficacy and safety of CBD in psychiatry is still scarce. Further larger well-designed randomized controlled trials are required to assess the effects of CBD in psychiatric disorders.

47. Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neurosci Biobehav Rev. 2017;72:310–24.

48. Blessing EM, Steenkamp MM, Marnazanes J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12:825–36.

49. de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, Machado S, Arias-Carrion O, Crippa JA, Zuardi AW, Nardi AE, Silva AC. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurosci Drug Disc Targets. 2014;13:953–60.

50. De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, Aboud M, Maione S, Comai S, Gobbi G. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain. 2019;160:136–50.

51. Pretzsch CM, Voinescu B, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Williams S, Murphy DG, Daly E, et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol. 2019;33:1141–8.

52. Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24:51–64.

53. Deiana S. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug Test Anal. 2013;5:45–51.

54. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.

55. Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D’Souza DC, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia in a randomized placebo controlled trial. Psychopharmacology. 2018;235:1923–32.
in males and females in two different rat models of depression. Physiol Behav. 2019;201:59–63.

65. Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol. 2005;19:293–300.

66. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011;124:250–61.

67. Zuardi A, Crippa J, Dursun S, Morais S, Vilela J, Sanches R, Hallak J. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 2010;24:135–7.

68. Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, Trzesniak C, Tumas V, Dursun S, Chagas MH, et al. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol. 2011;25:274–80.

69. Libro R, Diomede F, Sciotti D, Piattelli A, Grassi G, Pollastro F, Bramanti P, Mazzon E, Trubiani O. Cannabidiol modulates the expression of Alzheimer’s disease-related genes in mesenchymal stem cells. Int J Mol Sci. 2016;18.

70. Abate G, Uberti D, Tambaro S. Potential and limits of cannabinoids in Alzheimer’s disease therapy. Biology (Basel). 2021;10.

71. Amini M, Abdolmaleki Z. The Effect of Cannabidiol Coated by Nano-Chitosan on Learning and Memory, Hippocampal CB1 and CB2 Levels, and Amyloid Plaques in an Alzheimer’s Disease Rat Model. Neuropsychobiology. 2022;81:171–83.

72. Watt G, Karl T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. Front Pharmacol. 2017;8:20.

73. Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28:1088–98.

74. Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39:564–6.

75. Zuardi AW, Crippa JA, Hallak JE, Pinto JO, Chagas MH, Rodrigues GG, Dursun SM, Tumas V. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009;23:979–83.

76. Giacoppo S, Pollastro F, Grassi G, Bramanti P, Mazzon E. Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Fittoterapia. 2017;116:77–84.

77. Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Abilio VC. Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? Front Pharmacol. 2018;9:482.

78. Libzon S, Schleider LB, Saban N, Levit L, Tamari Y, Linder I, Lerner-Sagi T, Blumkin L. Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders. J Child Neurol. 2018;33:565–71.

79. Lus G, Cantello R, Danni MC, Rini A, Sarchielli P, Tassinari V, Signoriello E. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study. Neurodegener Dis Manag. 2018;8:105–13.

80. Rudloff T, Sosnoff J. Cannabidiol to Improve Mobility in People with Multiple Sclerosis. Front Neurol. 2018;9:183.

81. Vermersch P, Trojano M. Tetrahydrocannabinol: Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. Eur Neurol. 2016;76:216–26.
Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction. 2018.

101. Beale C, Broidy SJ, Chye Y, Suo C, Schira M, Galetti P, Martin JH, Yücel M, Solowij N. Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. Cannabis Cannabinoid Res. 2018;3:94–107.

102. Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, Freeman AM, Lees R, Craft S, Morrison PD, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7:865–74. In a randomised clinical trial, the investigators showed that CBD at doses of 400mg and 800mg CBD were safe with no serious adverse effects and more effective than placebo at reducing cannabis use in people with cannabis use disorder. While the lower dose of 200 mg was ineffective.

103. Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, Barnes AJ, Huestis MA, George TP, Streiner DL, et al. Nabiloxmols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS One. 2018;13: e0190768. In this randomized controlled clinical trials, the investigators report that nabixomols (Sativex), a combination of 103 mgTHC and 105 mgCBD (nabiloxmols; Sativex) combined with MET/CBT was well tolerated and reduced cannabis use in people with CUD. Nevertheless, future clinical trials should explore the potential of high doses of nabiloxmols for cannabis dependence.

104. Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland I, McGregor I, Bruno R, Gugusheff J, Phung N, Montebello M, et al. Nabiloximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. JAMA Intern Med. 2019;179:1242–53.

105. Lintzeris N, Mills L, Dunlop A, Copeland J, McGregor I, Bruno R, Kirby A, Montebello M, Hall M, Jefferies M, et al. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug Alcohol Depend. 2020;215:108220.

106. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, et al. Nabiloximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71:281–91.

107. Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, Chagas MH, Zuardi AW. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 2013;38:162–4.

108. Shannon S, Opila-Lehman J. Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report. Integr Med (Encinitas). 2015;14:31–5.

109. Werneck MA, Kortas GT, de Andrade AG, Castaldelli-Maia JM. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. CNS Drugs. 2018;32:1113–29.

110. Hurd YL, Spriggs S, Alishaye Y, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019;176:911–22. In this first clinical trial with people with opiate use disorder (OUD), although in a small number of subjects, the investigators have shown that acute CBD administration, in contrast to placebo, significantly reduced both craving and anxiety. In addition, CBD also reduced the drug cue-induced physiological measures of heart rate and salivary cortisol levels, and there were no serious adverse effects. They suggest that CBD has potential to reduce cue-induced craving and anxiety in people with opiate use disorders and these data provide a strong basis for further investigation of CBD as a treatment option for OUD. NOTE: A larger study is in progress ([https://clinicaltrials.gov](https://clinicaltrials.gov)).

111. National Academies of Sciences Medicine Health Medicine Board on Population Public Health Committee on the Health Effects of Marijuana: An Evidence and Research. The National Academies Collection: Reports funded by National Institutes of Health. In The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. (Washington (DC): National Academies Press (US); Copyright 2017 by the National Academy of Sciences. All rights reserved. 2017.

112. Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O’Sullivan SE, Tan GD. Efficacy and Safety of Cannabidiol and Tetrahydrocannabinol in Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care. 2016;39:1777–86.

113. Sultan SR, Millar SA, England TJ, O’Sullivan SE. A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol. Front Pharmacol. 2017;8:81.

114. Jadoon KA, Tan GD, O’Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017;2.

115. Hayakawa K, Mishima K, Fujiwara M. Therapeutic Potential of Non-Psychoactive Cannabinoid in Ischemic Stroke. Pharmaceuticals (Basel). 2010;3:2197–212.

116. Kalenderoglou N, Macpherson T, Wright KL. Cannabidiol Reduces Leukemic Cell Size - But Is It Important? Front Pharmacol. 2017;8:144.

117. Lowe HI, Toyang NJ, McLaughlin W. Potential of Cannabidiol for the Treatment of Viral Hepatitis. Pharmacognosy Res. 2017;9:116–8.

118. Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, et al. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol. 2012;167:1218–31.

119. Böckmann S, Hinz B. Cannabidiol Promotes Endothelial Cell Survival by Heme Oxygenase-1-Mediated Autophagy. Cells. 2020;9.

120. Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D, Gabbard JD, Chen SN, Ohtsuki T, Friesen JB et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2020;6:eaax6110.

121. Lal S, Shekher A, Puneet, Narula AS, Abrahamse H, Gupta SC. Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities. Pharmacol Res 2021;163:105302.

122. Sawtell L, Holle LM. Use of Cannabis and Cannabinoids in Patients With Cancer. Ann Pharmacother. 2021;55:870–90.

123. Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychootropic cannabinoid. Carcinogenesis. 2014;35:2787–97.

124. Pagano C, Navarra G, Coppola L, Bifulco M, Laezza C. Molecular Mechanism of Cannabinoids in Cancer Progression. Int J Mol Sci. 2021;22.

125. Raup-Konsavage WM, Johnson M, Legare CA, Yochum GS, Morgan DJ, Vrana KE. Synthetic Cannabinoid Activity Against Colorectal Cancer Cells. Cannabis Cannabinoid Res. 2018;3:272–81.

126. Shah SA, Gupta AS, Kumar P. Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2
receptor agonists in cancer treatment and chemotherapy-associated cancer management. J Cancer Res Ther. 2021;17:1–9.

127. Turner CE, Elsohy MA. Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol. 1981;21:283s–91s.

128. Davis WM, Hatoum NS. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Gen Pharmacol. 1983;14:247–52.

129. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, de Novellis V, Di Marzo V. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol. 2011;162:584–96.

130. El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D, Khan I, ElSohly M, Ross S. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacochem Behav. 2010;95:434–42.

131. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006;318:1375–87.

132. Shinjyo N, Di Marzo V. The effect of cannabichromene on adult neural stem/progenitor cells. Neurochem Int. 2013;63:432–7.

133. Petrosoin S, Verde R, Vaia M, Allarà M, Iuvone T, Di Marzo V. Anti-inflammatory Properties of Cannabidiol, a Nonpsychoactive Cannabinoid, in Experimental Allergic Contact Dermatitis. J Pharmacol Exp Ther. 2018;365:652–63.

134. Oláh A, Markovics A, Szabó-Papp J, Szabó PT, Stott C, Zouboulis CC, Bíró T. Differential effectiveness of selected non-psychoactive cannabinoid photoproducts on human sebocyte functions implicates their introduction in dry/seborrhoic skin and acne treatment. Exp Dermatol. 2016;25:701–7.

135. Chandra S, Lata H, ElSohly MA, Walker LA, Potter D. Cannabis cultivation: Methodological issues for obtaining medical-grade product. Epilepsy Behav. 2017;70:302–12.

136. Turner SE, Williams CM, Iversen L, Whalley BJ. Molecular Pharmacology of Phytocannabinoids. Prog Chem Org Nat Prod. 2017;103:61–101.

137. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70:313–8.

138. Morano A, Cifelli P, Nencini P, Antonilli L, Fattouch J, Ruffolo G, Rosseti C, Aronica E, Limatola C, Di Bonaventura C, et al. Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidiavirin. Epilepsia Open. 2016;1:145–51.

139. Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, Futamura T, Duncan M, Stott CG, Stephens GJ, et al. Cannabidiavirin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012;167:1629–42.

140. Amada N, Yamasaki Y, Williams CM, Whalley BJ. Cannabidiavirin (CBDV) suppresses pentyleneetetrazole (PTZ)-induced increases in epilepsy-related gene expression. Periph. 2013;1:e214.

141. Rock EM, Sticht MA, Duncan M, Stott C, Parker LA. Evaluation of the potential of the phytocannabinoids, cannabidiavirin (CBDV) and Delta(9)-tetrahydrocannabinavirin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol. 2013;170:671–8.

142. Pretzsch CM, Voinescu B, Lyngbye D, Horder J, Mendez MA, Wichters R, Ajram L, Ivin G, Heasman M, Edden RA, et al. Effects of cannabidiavirin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. Transl Psychiatry. 2019;9:313.

143. Zamberletti E, Rubino T, Parolaro D. Therapeutic potential of cannabidiavirin for epilepsy and autism spectrum disorder. Pharmacol Ther. 2021;226:107878.

144. Loss CM, Teodor L, Rodrigues GD, Moreira LR, Peres FF, Zuardi AW, Crippa JA, Hallak JE, Abilio VC. Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? Front Pharmacol. 2020;11:635763.

145. Alves P, Amaral C, Teixeira N, Correia-da-Silva G. Cannabidiavirin: Much more beyond Δ(9)-tetrahydrocannabinol. Pharmacol Res. 2020;157:104822.

146. Bar-Lev Schleider L, Mchoulam R, Saban N, Meiri G, Novack V. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci Rep. 2019;9:200.

147. Horváth B, Mukhopadhyay P, Haskó G, Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol. 2012;180:432–42.

148. Bátkai S, Mukhopadhyay P, Horváth B, Rajesh M, Gao Y, Mahadevan A, Amere M, Battista N, Lichtman AH, Gauson LA, et al. Δ8-Tetrahydrocannabinavirin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol. 2012;165:2450–61.

149. Englund A, Atakan Z, Kralj A, Tunstall N, Murray R, Morrison P. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol. 2016;30:140–51.

150. Khalsa J, Bunt G, Galanter M, Wetterau R. Medical uses of cannabis and cannabinoids. In: Shannon Miller DF, Rosenthal RN, Saiz R, editors. The ASAM Principles of Addiction Medicine. 6th Edition. Wolter Kluwer;2019.

151. Granja AG, Carrillo-Salinas F, Pagani A, Gómez-Cañas M, Negri R, Navarrete C, Meca M, Mestre L, Fiebich BL, Cantarero I, et al. A cannabinol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J Neuroimmune Pharmacol. 2012;7:1002–16.

152. Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci. 2007;45:87–92.

153. Baek SH, Kim YO, Kwag JS, Choi KE, Jung WY, Han DS, Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabinol against human oral epitheloid carcinoma cells. Arch Pharm Res. 1998;21:353–6.

154. Merkus FW, Jaspers MG, Roovers JK. Discovery of cannabis and cannabinoids. In: Shannon Miller DF, Rosenthal RN, Saiz R, editors. The ASAM Principles of Addiction Medicine. 6th Edition. Wolter Kluwer;2019.

155. Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metab Dispos. 2021;49:1070–80.

156. Doohan PT, Oldfield LD, Arnold JC, Anderson LL. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metab Dispos. 2021;49:1070–80.

157. Dean L, Kane M. Dronabinol Therapy and CYP2C9 Genotype. Interactions with Cytochrome P450 Drug Metabolism: a Full-Text Review. Aaps j. 2021;23:91.

158. MacDonald E, Adams A. CADTH Rapid response reports. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Dean L, Kane M. Dronabinol Therapy and CYP2C9 Genotype. Interactions with Cytochrome P450 Drug Metabolism: a Full-Text Review. Aaps j. 2021;23:91.

159. Rong C, Carmona NE, Lee YL, Raggvet RM, Pan Z, Rosenblat JD, Subramaniapillai M, Shekotikhina M, Almatham F, Alageel
A, et al. Drug-drug interactions as a result of co-administering Δ(9)-THC and CBD with other psychotropic agents. Expert Opin Drug Saf. 2018;17:51–4.

160. Singh A, Bilichak A, Kovalchuk I. The genetics of Cannabis-genomic variations of key synthases and their effect on cannabinoid content. Genome. 2021;64:490–501.

161. Liu Y, Zhu P, Cai S, Haughn G, Page JE. Three novel transcription factors involved in cannabinoid biosynthesis in Cannabis sativa L. Plant Mol Biol. 2021;106:49–65.

162. Vergara D, Huscher EL, Keepers KG, Pisupati R, Schwabe AL, McGlaughlin ME, Kane NC. Genomic Evidence That Governmentally Produced Cannabis sativa Poorly Represents Genetic Variation Available in State Markets. Front Plant Sci. 2021;12:668315.

163. Maguire RF, Wilkinson DJ, England TJ, O’Sullivan SE. The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines. Med Cannabis Cannabinoids. 2021;4:86–96.

164. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Front Plant Sci. 2016;7:19.

165. Radwan MM, Chandra S, Gul S, ElSohly MA. Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis. Molecules. 2021;26.

166. Noel C. Evidence for the use of “medical marijuana” in psychiatric and neurologic disorders. Ment Health Clin. 2017;7:29–38.

167. American Psychiatric Association. Position statement in opposition to cannabis as medicine. (American Psychiatric Association). Position Statement Template. 2019. psychiatry.org. Accessed 08 05 2022.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Jag H. Khalsa1,2,3 · Gregory Bunt4 · Kenneth Blum5,6,7,8,9,10 · Sanjay B. Maggirwar2 · Marc Galanter11 · Marc N. Potenza12

Gregory Bunt
buntm@gmail.com

Kenneth Blum
drd2gene@gmail.com

Sanjay B. Maggirwar
smaggirwar@gwu.edu

Marc Galanter
marcgalanter@nyu.edu

Marc N. Potenza
marc.potenza@yale.edu

1 Division of Therapeutics and Medical Consequences, Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse, NIH, Special Volunteer, 16071 Industrial Drive, Gaithersburg, MD 20877, USA

2 Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University School of Medicine, Ross Hall Room 502A, 2300 I Street, Washington, NWDC 20037, USA

3 Drug Addiction and Co-occurring Infections, Aldie, VA 20105-5572, USA

4 Samaritan Day Top Village, NYU School of Medicine, 550 First Ave, New York, NY 10016, USA

5 Center for Behavioral Health & Sports, Western University Health Sciences, Pomona, CA, USA

6 Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary

7 Division of Nutrigenomics, Precision Translational Medicine, LLC, San Antonio, TX, USA

8 Division of Nutrigenomics, Institute of Behavior & Neurogenetics, LLC, San Antonio, TX, USA

9 Department of Psychiatry, University of Vermont, Burlington, VT, USA

10 Department of Psychiatry, Wright University Boonshoff School of Medicine, Dayton, OH, USA

11 Department of Psychiatry, NYU School of Medicine, 550 First Avenue, Room NBV20N28, New York, NY 10016, USA

12 Departments of Psychiatry and Neuroscience and the Child Study Center, Yale School of Medicine, 1 Church Street, Rm726, New Haven, CT 06510, USA